[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589073":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":63,"collaborators":67,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":82,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET\u002FCT or MRI imaging within the specificed time.",[13],"Diagnostic Test: 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ying Wang, MD","CONTACT","+8618702292537","macrossplusvoices@163.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Li Cai, MD","+862260362190","xcl242004@126.com",[30,49],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","350005","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.28083,31.86389,{"lat":42,"lon":41},[45],{"name":46,"role":22,"phone":47,"phoneExt":10,"email":48},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"facility":50,"status":32,"city":51,"state":52,"zip":53,"country":36,"countryCode":37,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052",{"type":39,"coordinates":55},[56,57],117.17667,39.14222,{"lat":57,"lon":56},[60,61],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":21,"role":62,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[68],{"name":50,"class":6},"100589073","alpha-synuclein-petct-in-various--syn-related-disease-100589073",false,"NCT06949670","Alpha-Synuclein PET\u002FCT in Various α-Syn-Related Disease","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":80,"type":81},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.",[86,87,88],"Alpha Synuclein Pathology","Alpha-Synuclein","Parkinson Disease",[90,91,87],"PET\u002FCT","MRI","2026-01-27",{"date":94,"type":95},"2026-01-29","ACTUAL",{"date":97,"type":95},"2025-04-01",{"date":99,"type":81},"2028-04-01",{"name":5,"class":6},2]